Literature DB >> 12107813

Apolipoprotein E gene in frontotemporal dementia: an association study and meta-analysis.

Patrice Verpillat1, Agnès Camuzat, Didier Hannequin, Catherine Thomas-Anterion, Michèle Puel, Serge Belliard, Bruno Dubois, Mira Didic, Lucette Lacomblez, Olivier Moreaud, Véronique Golfier, Dominique Campion, Alexis Brice, Françoise Clerget-Darpoux.   

Abstract

No definite genetic risk factor of non-monogenic frontotemporal dementia (FTD) has yet been identified. Several groups have examined the potential association of FTD with the apolipoprotein E (APOE) gene, but the results are inconsistent. Our objective was to determine whether APOE is a risk factor of FTD, using the largest series of patients with FTD and controls analysed so far (94 unrelated patients and 392 age and sex-matched controls), and a meta-analysis. Homozygosity for the E2E2 genotype was significantly associated with FTD (odds ratio (OR)=11.3; P=0.033, exact test). After stratification on familial history (FH) for FTD, the OR for E2E2 was still found significant when analysing only patients with a positive FH (OR=23.8; P=0.019). The meta-analysis, using 10 case-control studies with available genotype or allele information, comprising a total of 364 FTD patients and 2671 controls, including the patients of the present study, did not reach statistical significance even if the E2E2 genotype was more frequent in patients than in controls (0.018 vs 0.006, respectively). Because of studies heterogeneity (Mantel-Haenszel statistics: P=0.004), we analysed on one hand the neuropathologically-confirmed studies, and on the other hand the clinical-based studies. In the neuropathologically-confirmed studies (Mantel-Haenszel statistics: P=ns), we found a significant increase of the E2 allele frequency in FTD patients (OR[E2 vs E3]=2.01; 95% CI=1.02-3.98; P=0.04). The same result was found in the clinical-based studies, but studies heterogeneity remained. No result was significant with the E4 allele. The E2 allele seems so to be a risk factor of FTD whereas this allele is associated with the lowest risk in Alzheimer's disease. If this finding was confirmed, it could provide new insights into the mechanisms of differential risk related to APOE in neurodegenerative diseases.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12107813     DOI: 10.1038/sj.ejhg.5200820

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   4.246


  30 in total

Review 1.  Frontotemporal dementia.

Authors:  Erik D Roberson
Journal:  Curr Neurol Neurosci Rep       Date:  2006-11       Impact factor: 5.081

Review 2.  Frontotemporal lobar degeneration: current knowledge and future challenges.

Authors:  Chiara Cerami; Elio Scarpini; Stefano F Cappa; Daniela Galimberti
Journal:  J Neurol       Date:  2012-04-25       Impact factor: 4.849

3.  Apolipoprotein Ε ε4 frequency is increased among Chinese patients with frontotemporal dementia and Alzheimer's disease.

Authors:  Yong Ji; Mengyuan Liu; Ya Ruth Huo; Shuling Liu; Zhihong Shi; Shuai Liu; Thomas Wisniewski; Jinhuan Wang
Journal:  Dement Geriatr Cogn Disord       Date:  2013-07-23       Impact factor: 2.959

4.  Identification of misdiagnosed fronto-temporal dementia using APOE genotype and phenotype-genotype correlation analyses.

Authors:  Isabel Hernández; Ana Mauleón; Maiteé Rosense-Roca; Montserrat Alegret; Georgina Vinyes; Anna Espinosa; Oscar Sotolongo-Grau; James T Becker; Sergi Valero; Lluís Tarraga; Oscar L López; Agustín Ruiz; Mercè Boada
Journal:  Curr Alzheimer Res       Date:  2014-02       Impact factor: 3.498

Review 5.  A Quarter Century of APOE and Alzheimer's Disease: Progress to Date and the Path Forward.

Authors:  Michaël E Belloy; Valerio Napolioni; Michael D Greicius
Journal:  Neuron       Date:  2019-03-06       Impact factor: 17.173

6.  The behavioural/dysexecutive variant of Alzheimer's disease: clinical, neuroimaging and pathological features.

Authors:  Rik Ossenkoppele; Yolande A L Pijnenburg; David C Perry; Brendan I Cohn-Sheehy; Nienke M E Scheltens; Jacob W Vogel; Joel H Kramer; Annelies E van der Vlies; Renaud La Joie; Howard J Rosen; Wiesje M van der Flier; Lea T Grinberg; Annemieke J Rozemuller; Eric J Huang; Bart N M van Berckel; Bruce L Miller; Frederik Barkhof; William J Jagust; Philip Scheltens; William W Seeley; Gil D Rabinovici
Journal:  Brain       Date:  2015-07-02       Impact factor: 13.501

Review 7.  The genetic epidemiology of neurodegenerative disease.

Authors:  Lars Bertram; Rudolph E Tanzi
Journal:  J Clin Invest       Date:  2005-06       Impact factor: 14.808

Review 8.  The genetics of frontotemporal lobar degeneration.

Authors:  Rosa Rademakers; Mike Hutton
Journal:  Curr Neurol Neurosci Rep       Date:  2007-09       Impact factor: 5.081

Review 9.  Glycosylation and other PTMs alterations in neurodegenerative diseases: Current status and future role in neurotrauma.

Authors:  Hussein Abou-Abbass; Hadi Abou-El-Hassan; Hisham Bahmad; Kazem Zibara; Abir Zebian; Rabab Youssef; Joy Ismail; Rui Zhu; Shiyue Zhou; Xue Dong; Mayse Nasser; Marwan Bahmad; Hala Darwish; Yehia Mechref; Firas Kobeissy
Journal:  Electrophoresis       Date:  2016-04-04       Impact factor: 3.535

10.  [Frontotemporal dementia in association with a family history of dementia and ApoE polymorphism].

Authors:  M Zintl; M Petkov; G Schmitz; G Hajak; H-H Klünemann
Journal:  Nervenarzt       Date:  2010-01       Impact factor: 1.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.